Investors

Recent Releases

March 20, 2025

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

GAITHERSBURG, Md. , March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly

March 20, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md. , March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC ( Hikma, Group ), the multinational generic pharmaceutical

March 19, 2025

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

GAITHERSBURG, Md. , March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore -Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is